Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib in MAPK-mutated solid cancers
NCT05054374Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirdametinib in solid tumor (advanced stage), breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2021; status: completed.
02
Drugs
mirdametinib
03
Conditions
solid tumor (advanced stage)breast cancer
Beyond the preview
Go deeper on NCT05054374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054374.